维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09887 维立志博-B

未开盘 03-19 16:08:15

63.400

-2.400

-3.65%

最高65.700	最低62.450	成交量43.94万
今开65.450	昨收65.800	日振幅4.94%
总市值126.17亿	流通市值97.00亿	总股本1.99亿
成交额2,805万	换手率0.29%	流通股本1.53亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"维立志博-B","latestPrice":63.4,"timestamp":1773907695003,"preClose":65.8,"halted":0,"volume":439400,"delay":0,"changeRate":-0.03647416413373858,"floatShares":153000000,"shares":199000000,"eps":-2.008042,"marketStatus":"未开盘","change":-2.4,"latestTime":"03-19 16:08:15","open":65.45,"high":65.7,"low":62.45,"amount":28054334,"amplitude":0.049392,"askPrice":63.5,"askSize":1300,"bidPrice":63,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-1.583,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773970200000},"marketStatusCode":0,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":65.8,"openAndCloseTimeList":[[1773883800000,1773892800000],[1773896400000,1773907200000]],"volumeRatio":0.716997,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09887","defaultTab":"news","newsList":[{"id":"2618761585","title":"维立志博-B盘中涨超8% 正式进入港股通股票名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2618761585","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618761585?lang=zh_cn&edition=full","pubTime":"2026-03-09 10:35","pubTimestamp":1773023700,"startTime":"0","endTime":"0","summary":"　　维立志博-B盘初涨超8%，截至发稿，股价上涨6.04%，现报57.10港元，成交额1.15亿港元。　　维立志博公布，自2026年3月9日起，公司股份将获恒生指数有限公司纳入恒生综合指数成份股及获调入港股通标的名单。　　此外，3月6日，维立志博宣布，公司自主研发的PD-L1/4-1BB双特异性抗体维利信联合用药一线治疗局部晚期或转移性食管鳞癌的Ⅱ期临床研究顺利完成首例患者入组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-03-09/doc-inhqizzu7097010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09887","BK1161","HK0000500386.USD","HK0000252152.HKD","VXUS","BK4585","HK0000252160.HKD","VT","BK4588"],"gpt_icon":0},{"id":"2617666837","title":"维立志博-B获纳入恒生综合指数成份股及获调入港股通股票名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2617666837","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617666837?lang=zh_cn&edition=full","pubTime":"2026-03-08 10:08","pubTimestamp":1772935680,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　维立志博-B（09887）发布公告，自2026年3月9日起，公司股份将获恒生指数有限公司纳入恒生综合指数成份股及获调入港股通标的名单。\n　　股份获纳入恒生综合指数及港股通标的证券是资本市场对公司表现及价值的高度认可，并允许中国内地合资格投资者透过沪港通及深港通机制直接投资于香港联合交易所有限公司上市的股份。预期纳入将进一步扩大公司的投资者基础，提升股份的交易流动性，并进一步优化股东结构。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-03-08/doc-inhqfsuq1032680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["VXUS","HSCI","HK0000500386.USD","VT","HK0000252152.HKD","HK0000252160.HKD","09887","BK1161","BK4588","BK4585"],"gpt_icon":0},{"id":"2617857206","title":"维立志博-B(09887)获纳入恒生综合指数成份股及获调入港股通股票名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2617857206","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617857206?lang=zh_cn&edition=full","pubTime":"2026-03-06 17:15","pubTimestamp":1772788549,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，自2026年3月9日起，公司股份将获恒生指数有限公司纳入恒生综合指数成份股及获调入港股通标的名单。股份获纳入恒生综合指数及港股通标的证券是资本市场对公司表现及价值的高度认可，并允许中国内地合资格投资者透过沪港通及深港通机制直接投资于香港联合交易所有限公司上市的股份。预期纳入将进一步扩大公司的投资者基础，提升股份的交易流动性，并进一步优化股东结构。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HSCI","09887","VXUS","HK0000252160.HKD","HK0000500386.USD","BK4585","BK1161","HK0000252152.HKD","VT","BK4588"],"gpt_icon":0},{"id":"2617683670","title":"维立志博-B(09887)：维利信™于一线食管鳞状细胞癌II期试验的首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2617683670","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617683670?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:33","pubTimestamp":1772786017,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，评价维利信™(PD-L1/4-1BB双特异性抗体奥帕替苏米单抗，LBL-024)用于治疗一线食管鳞状细胞癌的II期临床研究首例患者已成功入组。本次开展的开放标签、多中心Ⅱ期临床研究由北京大学肿瘤医院沈琳院长牵头，正在全国多家医院同步推进。该试验旨在评价奥帕替苏米单抗用于治疗一线食管鳞状细胞癌患者的有效性和安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","HK0000500386.USD","BK1161","HK0000252160.HKD","HK0000252152.HKD"],"gpt_icon":0},{"id":"2616320220","title":"每日卖空追踪 | 维立志博-B 03月03日卖空量成交2.08万股，卖空比例为3.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616320220","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616320220?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:30","pubTimestamp":1772526644,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间03月03日，跌8.16%，卖空量成交2.08万股，较上一交易日减少43.48%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303163623a445cefd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303163623a445cefd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000252152.HKD","HK0000252160.HKD","09887","BK1161","HK0000500386.USD"],"gpt_icon":0},{"id":"2616784320","title":"维立志博-B03月03日主力净流出118.0万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2616784320","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616784320?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:15","pubTimestamp":1772525722,"startTime":"0","endTime":"0","summary":"03月03日, 维立志博-B股价跌8.16%，报收54.60元，成交金额2966.0万元，换手率0.34%，振幅13.04%，量比1.83。维立志博-B今日主力资金净流出118.0万元，上一交易日主力净流入157.1万元。该股近5个交易日下跌17.61%，主力资金累计净流出149.4万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入4366.1万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303161619a445b5e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303161619a445b5e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000252160.HKD","HK0000500386.USD","09887","BK1161","HK0000252152.HKD"],"gpt_icon":0},{"id":"1100714503","title":"维立志博生物科技（09887）2026年2月月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1100714503","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100714503?lang=zh_cn&edition=full","pubTime":"2026-03-03 12:25","pubTimestamp":1772511938,"startTime":"0","endTime":"0","summary":"维立志博生物科技有限公司（09887）于2026年3月3日发布2026年2月股份变动月报表。公告显示，截至2026年2月28日，公司的注册股本总额为人民币198,891,800元，与上月持平，维持不变。\n公司目前拥有两类股份：其中H股已发行股份153,278,691股，未上市普通股则为45,613,109股。报告期内并未出现新增发行、购回、注销或库藏股变动，公司股本结构保持稳定。\n此外，公告确认公司已满足香港联合交易所有限公司相关上市规则的公众持股量要求。根据公告内容，公司承诺遵守所有适用的上市规则、法律及监管规定，所有权文件及履行程序均已合规完成。\n本次公告由联席公司秘书左洪刚签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"2614686513","title":"每日卖空追踪 | 维立志博-B 02月27日卖空量成交1.31万股，卖空比例为6.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614686513","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614686513?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:30","pubTimestamp":1772181043,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间02月27日，涨1.54%，卖空量成交1.31万股，较上一交易日减少69.89%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227163618a4367ac4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227163618a4367ac4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000500386.USD","BK1161","HK0000252160.HKD","HK0000252152.HKD","09887"],"gpt_icon":0},{"id":"2614073006","title":"每日卖空追踪 | 维立志博-B 02月26日卖空量成交2.38万股，卖空比例为9.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614073006","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614073006?lang=zh_cn&edition=full","pubTime":"2026-02-26 16:30","pubTimestamp":1772094642,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间02月26日，跌3.21%，卖空量成交2.38万股，较上一交易日增加16.1%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226163623a7219d34&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226163623a7219d34&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887","HK0000500386.USD","HK0000252160.HKD","HK0000252152.HKD"],"gpt_icon":0},{"id":"2614073000","title":"维立志博-B02月26日遭主力抛售90.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614073000","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614073000?lang=zh_cn&edition=full","pubTime":"2026-02-26 16:15","pubTimestamp":1772093753,"startTime":"0","endTime":"0","summary":"02月26日, 维立志博-B股价跌3.21%，报收61.75元，成交金额1588.8万元，换手率0.17%，振幅4.94%，量比0.59。维立志博-B今日主力资金净流出90.9万元，连续3日净流出，上一交易日主力净流出63.4万元。该股近5个交易日下跌5.73%，主力资金累计净流入253.0万元；近20日主力资金累计净流入5550.7万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226162015a7218a00&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226162015a7218a00&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000500386.USD","09887","HK0000252152.HKD","HK0000252160.HKD","BK1161"],"gpt_icon":0},{"id":"2613262766","title":"每日卖空追踪 | 维立志博-B 02月23日卖空量成交2.81万股，卖空比例为4.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613262766","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613262766?lang=zh_cn&edition=full","pubTime":"2026-02-23 16:30","pubTimestamp":1771835443,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间02月23日，涨5.77%，卖空量成交2.81万股，较上一交易日增加301.43%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223163550a4be7eea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223163550a4be7eea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","HK0000252152.HKD","HK0000500386.USD","HK0000252160.HKD","BK1161"],"gpt_icon":0},{"id":"2613967204","title":"维立志博-B午后上涨6% 公司下月有望成为港股通标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2613967204","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613967204?lang=zh_cn&edition=full","pubTime":"2026-02-23 14:51","pubTimestamp":1771829460,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　维立志博-B（09887）午后股价上涨6%，现报68.90港元，成交额3078.41万港元。\n　　恒生指数公司此前宣布季度检讨结果，维立志博获纳入恒生综合指数，所有变动将于3月6日收市后实施并于3月9日起生效。中金发布研报指，维立志博3月有可能被调入港股通。西部证券则表示，考虑到公司2026年临床数据催化较多，2027年有望进入商业化拐点。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-02-23/doc-inhnusxe6044217.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["VT","09887","VXUS","BK4588","HK0000252152.HKD","HK0000500386.USD","HK0000252160.HKD","BK4585","BK1161"],"gpt_icon":0},{"id":"2612626178","title":"每日卖空追踪 | 维立志博-B 02月20日卖空量成交4700股，卖空比例为1.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612626178","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612626178?lang=zh_cn&edition=full","pubTime":"2026-02-20 16:30","pubTimestamp":1771576240,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间02月20日，跌0.76%，卖空量成交4700股，较上一交易日减少83.79%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220163555a70cd18e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220163555a70cd18e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161","HK0000252160.HKD","HK0000500386.USD","HK0000252152.HKD"],"gpt_icon":0},{"id":"2612252506","title":"IO2.0争夺战打响，下一代肿瘤“药王”花落谁家？","url":"https://stock-news.laohu8.com/highlight/detail?id=2612252506","media":"药创新","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612252506?lang=zh_cn&edition=full","pubTime":"2026-02-20 15:00","pubTimestamp":1771570819,"startTime":"0","endTime":"0","summary":"下一代肿瘤“药王”争夺战打响！撰文丨粽哥2025下一代肿瘤“药王”，极有可能诞生于PD-1+X领域。以K药为代表的PD-1单抗，开启了一代IO治疗时代，但却存在耐药和冷肿瘤缺乏应答的问题。临床上，T细胞耗竭现象是导致免疫检查点获得性耐药的关键机制。TIGIT是经典免疫逃逸靶点，在多种淋巴细胞上表达，被认为是“下一个PD-1”。不过，PD-1/TIGIT双抗或有望打破TIGIT“难以成药”的魔咒。TIGIT和PD-1表达之间存在很强的相关性，特别是在肺癌的肿瘤浸","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602201513389541818d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602201513389541818d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1794554557.SGD","09926","01801","BK1161","LU1961090484.USD","LU0634319403.HKD","IE00B5MMRT66.SGD","LU0348784397.USD","LU0348825331.USD","LU0348827113.USD","02898","LU0417516902.SGD","LU0417516738.SGD","IE00B543WZ88.USD","LU0417516571.SGD","LU2476274720.SGD","LU0348735423.USD","LU0348766576.USD","LU0348783233.USD","LU2778985437.USD","02696","LU1720050803.USD","IE00BPRC5H50.USD","09995","LU2399975544.HKD","LU0561508036.HKD","01530","02616","09887","01177","LU2476274308.USD","LU2488822045.USD","LU0348767384.USD","BK1574","LU0540923850.HKD","01877"],"gpt_icon":1},{"id":"2612204261","title":"【券商聚焦】西部证券首予维立志博-B“买入”评级 指公司核心产品临床数据亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2612204261","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612204261?lang=zh_cn&edition=full","pubTime":"2026-02-20 10:04","pubTimestamp":1771553054,"startTime":"0","endTime":"0","summary":"金吾财讯|西部证券发布研报指，维立志博-B核心产品LBL-024在肺外神经内分泌癌临床数据优异，单药治疗3L+ EP-NEC ORR达33.3%，计划2026Q3递交BLA；LBL-034在复发难治多发性骨髓瘤I期ORR达82.5%。研报指出，LBL-024是全球首个进入注册临床的4-1BB靶向药物，已布局12个适应症，9项临床试验进行中。目标价未披露，首次覆盖给予\"买入\"评级。主要风险包括临床开发进度不及预期、商业化风险及核心人员流失。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220102227a70bf099&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220102227a70bf099&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887"],"gpt_icon":0},{"id":"2611170478","title":"维立志博-B午前涨逾8% 公司获纳入恒生综合指数有望入通","url":"https://stock-news.laohu8.com/highlight/detail?id=2611170478","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611170478?lang=zh_cn&edition=full","pubTime":"2026-02-16 11:23","pubTimestamp":1771212180,"startTime":"0","endTime":"0","summary":"　　维立志博-B午前股价上涨7.91%，现报66.20港元，成交额2843.92万港元。　　2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果，其中维立志博获纳入恒生综合指数。据中金研报，维立志博有可能被调入港股通，因其满足了包括市值、流动性和上市时间等在内的一系列标准。　　近日，维立志博公告，评价维利信用于治疗复发性或转移性三阴性乳腺癌的Ib/II期临床研究首例患者已成功用药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-02-16/doc-inhmyquq0261042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HSCI","09887","HK0000500386.USD","HK0000252152.HKD","BK1161","HK0000252160.HKD"],"gpt_icon":0},{"id":"2611824169","title":"维立志博-B02月13日主力净流入605.1万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2611824169","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611824169?lang=zh_cn&edition=full","pubTime":"2026-02-13 16:15","pubTimestamp":1770970515,"startTime":"0","endTime":"0","summary":"02月13日, 维立志博-B股价涨0.90%，报收61.35元，成交金额2257.8万元，换手率0.24%，振幅4.93%，量比1.03。维立志博-B今日主力资金净流入605.1万元，上一交易日主力净流出174.0万元。该股近5个交易日下跌1.59%，主力资金累计净流入116.9万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入4687.6万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213161544a6f6cfd3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213161544a6f6cfd3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000500386.USD","09887","HK0000252152.HKD","BK1161","HK0000252160.HKD"],"gpt_icon":0},{"id":"2610000912","title":"每日卖空追踪 | 维立志博-B 02月11日卖空量成交1.6万股，卖空比例为4.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610000912","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610000912?lang=zh_cn&edition=full","pubTime":"2026-02-11 16:30","pubTimestamp":1770798645,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间02月11日，跌5.11%，卖空量成交1.6万股，较上一交易日减少24.53%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211163617a4973342&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211163617a4973342&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000252160.HKD","HK0000252152.HKD","BK1161","09887","HK0000500386.USD"],"gpt_icon":0},{"id":"2610188859","title":"维立志博-B02月11日遭主力抛售263.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610188859","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610188859?lang=zh_cn&edition=full","pubTime":"2026-02-11 16:15","pubTimestamp":1770797717,"startTime":"0","endTime":"0","summary":"02月11日, 维立志博-B股价跌5.11%，报收60.40元，成交金额2035.8万元，换手率0.22%，振幅5.11%，量比0.80。维立志博-B今日主力资金净流出263.9万元，连续3日净流出，上一交易日主力净流出42.6万元。该股近5个交易日下跌7.59%，主力资金累计净流出233.6万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入4376.4万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211161554a4971b45&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211161554a4971b45&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD","BK1161"],"gpt_icon":0},{"id":"2610861798","title":"维立志博-B(09887)：维利信™于复发性或转移性三阴性乳腺癌IB/II期试验的首例患者用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2610861798","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610861798?lang=zh_cn&edition=full","pubTime":"2026-02-10 16:38","pubTimestamp":1770712703,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，评价维利信用于治疗复发性或转移性三阴性乳腺癌的Ib/II期临床研究首例患者已成功用药。该试验旨在评价奥帕替苏米单抗单独给药或联合白蛋白结合型紫杉醇治疗复发性或转移性三阴性乳腺癌患者的疗效及安全性。维利信亦有望成为治疗晚期肺外神经内分泌癌的首款获批药物。癌症是全球致病和致死的主要原因之一。在我国，乳腺癌每年新发病例数持续上升，估算达36万，死亡病例数达7.5万。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000500386.USD","BK1161","HK0000252152.HKD","09887","HK0000252160.HKD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.leadsbiolabs.com","stockEarnings":[{"period":"1week","weight":0.0209},{"period":"1month","weight":-0.0321},{"period":"3month","weight":0.2629},{"period":"6month","weight":-0.0063},{"period":"1year","weight":0.8114},{"period":"ytd","weight":0.2431}],"compareEarnings":[{"period":"1week","weight":-0.0084},{"period":"1month","weight":-0.0451},{"period":"3month","weight":-0.0074},{"period":"6month","weight":-0.0393},{"period":"1year","weight":0.0294},{"period":"ytd","weight":-0.0051}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"南京维立志博生物科技股份有限公司是一家主要从事发现、开发和商业化治疗肿瘤、自身免疫性疾病以及其他严重疾病的新疗法的中国公司。该公司的主要候选药物包括LBL-024、LBL-034、LBL-033、LBL-007等。该公司的LBL-024主要用于治疗肺外神经内分泌癌（EP-NEC）、小细胞肺癌（SCLC）、胆道癌（BTC）及非小细胞肺癌（NSCLC）、食管鳞状细胞癌（ESCC）、肝细胞癌（HCC）、胃癌（GC）及其他实体瘤。该公司还开发了专有技术平台，包括LeadsBody平台（CD3 T-cell engager平台）、X-body平台（4-1BB engager平台）以及其他几个双特异性抗体及融合蛋白平台。该公司主要在国内市场开展业务。","exchange":"SEHK","name":"维立志博-B","nameEN":"LEADS BIOLABS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"维立志博-B,09887,维立志博-B股票,维立志博-B股票老虎,维立志博-B股票老虎国际,维立志博-B行情,维立志博-B股票行情,维立志博-B股价,维立志博-B股市,维立志博-B股票价格,维立志博-B股票交易,维立志博-B股票购买,维立志博-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}